Imaging mass cytomETRY - Hyperion
Sirona Dx pioneered Imaging Mass Cytometry™ applications for biopharma, launching the world's first commercial service in 2018. A leading edge technology, IMC enables highly multiplexed immunohistochemistry (mIHC) with simultaneous detection of up to 38 protein markers in the same tissue section with subcellular, single cell resolution.
Retaining spatial information is key to accurately profile cells and understand their behavior in the context of the tissue microenvironment.
Sirona Dx offers the state-of-the-art Hyperion™ Imaging platform with a powerful image analysis software and expert IMC™ scientists from the leading laboratories in the field to help you characterize the tissue microenvironment, evaluate targeted biomarkers for preclinical and clinical samples and classify patients based on tissue biomarkers. The Hyperion™ Imaging Mass Cytometry System from Fluidigm uses metal-tagged antibodies combined with CyTOF® technology to simultaneously image up to 38 protein markers in a single scan, enabling in-depth characterization of protein biomarkers as well as measurement of signaling, hypoxia and immune markers.
Comprehensive End to End IMC Service includes:
o Antibody panel design (up to 38 markers)
o Custom antibody conjugation and verification
o Panel Optimization and validation (if required)
o Tissue processing: sectioning, pretreatment and staining
o Image acquisition using precise laser-directed capture & detection with CyTOF® technology
o Image analysis using secondary analysis software tools to help you:
- Identify & quantify cell populations in tissue (cancer stem cells, exhausted T effector cells, etc.)
- Neighbor analysis and cell social network to evaluate TIL, etc.
- Evaluate targeted biomarkers for preclinical and clinical samples
- Classify patients based on tissue biomarkers.
Applications of IMC™ include:
o Biomarker discovery and development
o Immuno-oncology
o Inflammatory and autoimmune diseases
o Neuro-immunology
o Characterization of tissue microenvironment
o Therapeutic response
o Drug safety and toxicity
o Oncology
